Vericel to Post Q1 2018 Earnings of ($0.12) Per Share, Leerink Swann Forecasts (VCEL)

Vericel (NASDAQ:VCEL) – Investment analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Vericel in a report released on Wednesday, April 4th. Leerink Swann analyst D. Antalffy anticipates that the biotechnology company will earn ($0.12) per share for the quarter. Leerink Swann currently has a “Outperform” rating and a $15.00 target price on the stock. Leerink Swann also issued estimates for Vericel’s Q2 2018 earnings at ($0.05) EPS, Q3 2018 earnings at ($0.09) EPS, Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.24) EPS, Q1 2019 earnings at ($0.08) EPS, Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at $0.08 EPS, FY2019 earnings at ($0.05) EPS, FY2020 earnings at $0.11 EPS, FY2021 earnings at $0.32 EPS and FY2022 earnings at $0.50 EPS.

How to Become a New Pot Stock Millionaire

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The company had revenue of $23.35 million for the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%.

A number of other brokerages have also recently commented on VCEL. ValuEngine raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BTIG Research set a $8.00 price objective on shares of Vericel and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Piper Jaffray lifted their price objective on shares of Vericel to $14.00 and gave the stock an “overweight” rating in a research note on Monday, March 5th. Needham & Company LLC lifted their price objective on shares of Vericel from $5.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Finally, Ladenburg Thalmann Financial Services cut shares of Vericel from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $14.25.

Shares of NASDAQ VCEL opened at $11.20 on Friday. Vericel has a 52-week low of $2.35 and a 52-week high of $12.80. The firm has a market capitalization of $406.30, a price-to-earnings ratio of -22.40 and a beta of 3.18. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.57 and a current ratio of 3.86.

Several large investors have recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Vericel by 35.2% in the 4th quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after buying an additional 11,509 shares in the last quarter. Perkins Capital Management Inc. grew its stake in shares of Vericel by 2.9% in the 4th quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock worth $3,155,000 after buying an additional 16,350 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Vericel in the 4th quarter worth $105,000. Bank of Montreal Can purchased a new position in shares of Vericel in the 4th quarter worth $140,000. Finally, Geode Capital Management LLC grew its stake in shares of Vericel by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 255,168 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 27,226 shares in the last quarter. 37.22% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This news story was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3336730/vericel-to-post-q1-2018-earnings-of-0-12-per-share-leerink-swann-forecasts-vcel.html.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

21Vianet Group  Receives Daily Media Impact Rating of 0.16
21Vianet Group Receives Daily Media Impact Rating of 0.16
Frontier Communications  Receives Coverage Optimism Score of 0.24
Frontier Communications Receives Coverage Optimism Score of 0.24
QAD  Receives News Sentiment Rating of 0.05
QAD Receives News Sentiment Rating of 0.05
Head-To-Head Contrast: Magellan Health  & Mednax
Head-To-Head Contrast: Magellan Health & Mednax
WA Space Trading Up 18.2% Over Last 7 Days
WA Space Trading Up 18.2% Over Last 7 Days
Sentinel Market Cap Reaches $0.00
Sentinel Market Cap Reaches $0.00


© 2006-2018 Ticker Report. Google+.